IL6R and cancer: Rather, the tocilizumab-mediated decrease in the fraction of cancer stem cells might be attributable to the differential expression of the receptor IL-6R, which is strongly expressed in ALDHhighCD44high cells when compared to ALDHlowCD44low cells (Figure 6G).